Press release
Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd., Honored as a 2025 Forbes China Pioneer Innovators in Industry Development
Amid the global trend of industrial innovation, the results of the "2025 Pioneer Innovators in Industry Development" selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. Dr. Yuxin Chen, with a strong academic background and solid capabilities in converting academic research into industrial applications, successfully led the global R&D and clinical development of multiple first-in-class (FIC) innovative drugs. The core products of ProteLight Pharmaceuticals, founded by Dr. Chen, have entered pivotal clinical trials in both China and the United States. They demonstrate outstanding original R&D capabilities and a forward-looking international development strategy. Dr. Chen was named a 2025 Forbes China Pioneer Innovator in Industry Development.
Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd.,
[Honored as a 2025 Forbes China Pioneer Innovators in Industry Development]
Image: https://www.globalnewslines.com/uploads/2025/05/495282c2facd6379eb09fc3c07020f15.jpg
Dr. Wang Xin, Global Partner and President of Sullivan Greater China, together with Professor Yu Wang, Expert Advisor to the Judging Committee and Chairman of Chinese Foundation for Hepatitis Prevention and Control, presented the award to Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd.
China's Pioneer in Antimicrobial Peptide Innovation: ProteLight Pharma's Peceleganan Ushers in a New Era of Anti-Infective Therapy
ProteLight Pharma has achieved a historic breakthrough in China's innovative drug development with its independently developed antimicrobial peptide spray Peceleganan (PL-5). It is the first antimicrobial peptide innovative drug in China to enter clinical trials and submit a New Drug Application (NDA), and it has also advanced to Phase II clinical trials in the United States. In addition, it has been granted the WHO International Nonproprietary Name (INN) "Peceleganan," marking the first time a Chinese-developed antimicrobial peptide compound has obtained an international nonproprietary name. Dr. Yuxin Chen, founder of ProteLight Pharma, proposed the revolutionary "Membrane Discrimination Mechanism," which fundamentally addresses the problem of antimicrobial resistance. In clinical trials, the Peceleganan spray demonstrated broad-spectrum efficacy, high potency, and a low potential for resistance. This breakthrough innovation received the "Peptide Application Special Award" at the 15th Chinese International Peptide Symposium. Based on this original mechanism, ProteLight Pharma has established a world-leading rational design platform for antimicrobial peptide drug development, along with an advanced formulation R&D platform for peptide drugs, laying a solid foundation for the future growth of its product pipelines.
A Full Value Chain Creator: An Outstanding Model of R&D Breakthroughs and Commercialization
ProteLight Pharma has signed an exclusive cooperation agreement with China's pharmaceutical giant Chia Tai Tianqing, which is responsible for the full-scale commercialization of the PL-5 spray in the Chinese market. The company is now valued at over 2 billion RMB and has secured more than 60 million RMB in funding from the national "12th Five-Year Plan" and "13th Five-Year Plan" Major New Drug Innovation Programs, as well as from provincial and municipal science and technology funds. Notably, PL-5 has demonstrated significantly better clinical efficacy than traditional antibiotics in treating difficult-to-heal infected wounds such as diabetic foot ulcers and extensive burns. It has consistently met primary endpoints across all phases of clinical trials, providing a Chinese solution to the global problem of drug-resistant bacterial infections. In addition to anti-infective therapies, ProteLight Pharma is also expanding into oncology, autoimmune diseases, and metabolic disorders. The company has already developed several preclinical-stage innovative drug candidates in these areas.
China's Strength in the Global Battle Against Antimicrobial Resistant Bacteria: Building a Sustainable Biopharmaceutical Innovation Engine
Facing the growing global crisis of antibiotic resistance, ProteLight Pharma is seizing the historic opportunity for antimicrobial peptide drug development and has laid out a clear development plan. Peceleganan is expected to obtain its new drug certificate in early 2026, and the follow-up product PL-18 is scheduled to enter Phase III clinical trials in China in the fourth quarter of 2025. The company is currently advancing its Round E financing, with a focus on strengthening its R&D system and expanding its product pipeline. Dr. Yuxin Chen emphasized that ProteLight Pharma will remain committed to continuous innovation based on its original technology platform. Through further development and application of the "Membrane Discrimination Mechanism," the company aims to systematically address key technical challenges from drug discovery to industrialization. Committed to tackling global public health challenges, ProteLight Pharma strives to become a global leader in the field of antimicrobial peptides. This strategic positioning reflects the company's strong sense of social responsibility and highlights the ambition and strength of Chinese innovative pharmaceutical companies in global health governance.
About Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd.
Founded in April 2009, Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. is a high-tech biopharmaceutical company focused on the research, development, and production of peptide and small-molecule drugs. The company is based in Jiangyin Hi-Tech Industrial Development Zone, Jiangsu Province, and is recognized as a National High Tech Enterprise. ProteLight Pharma has several subsidiaries, including wholly owned R&D subsidiaries Changchun ProteLight Pharmaceutical & Biotechnology Co., Ltd. and Nanjing Denovo Pharmaceutical Technology Co., Ltd., as well as Jiangsu Putai Pharmaceutical Technology Co., Ltd., ProteLight Medical Holdings (Hong Kong) Co., Ltd., and ProteLight Pharma (Australia) Pty Ltd.
Innovation-driven drug R&D and production is the core strategy of the company. It has built a diversified pipeline of first-in-class peptide and small-molecule innovative drugs, with a focus on anti-infective, oncology, autoimmune, and metabolic diseases. The company holds dozens of patents, including PCT international patents, U.S. and EU patents, Chinese invention patents, utility model patents, and design patents.
Since its founding, ProteLight Pharma has undertaken over 40 scientific research projects, including the national "Major New Drug Innovation" projects under the 12th and 13th Five-Year Plans, and the "Funding Program for Preferential Returned Scientific Research Students Innovative and Start-ups."
The company was selected as one of the first key entrepreneurial teams by the Overseas Chinese Affairs Office and was awarded the "Outstanding Entrepreneur Award".
Looking ahead, the company will continue to build on its antimicrobial peptide product foundation, maintaining a balanced focus on R&D and business operations. With high-quality innovative products, ProteLight Pharma aims to become a global leader in the field of antimicrobial peptide pharmaceuticals.
About the 2025 Forbes China Pioneer Innovators in Industry Development Selection
The "2025 Forbes China Pioneer Innovators in Industry Development" selection is jointly organized by Forbes China and Frost & Sullivan. It aims to identify and recognize entrepreneurs who demonstrate innovation and leadership in key areas such as life sciences, industry and energy, AI and information technology, and consumer finance and services. The evaluation process adopts rigorous data analysis and case study methodologies to comprehensively assess candidates' innovation strategies, market influence, and growth potential. This selection not only serves as an authoritative recognition of industry leaders, but also aims to inspire more entrepreneurs to embrace technological innovation and contribute to the sustainable development of their industries.
Media Contact
Company Name: Frost & Sullivan
Contact Person: Qian Li
Email: Send Email [http://www.universalpressrelease.com/?pr=dr-yuxin-chen-president-and-ceo-of-jiangsu-protelight-pharmaceutical-biotechnology-co-ltd-honored-as-a-2025-forbes-china-pioneer-innovators-in-industry-development]
Country: China
Website: http://www.frostchina.com
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd., Honored as a 2025 Forbes China Pioneer Innovators in Industry Development here
News-ID: 4009178 • Views: …
More Releases from Getnews
Pockefy Registered Elevates Surfwear with Premium Crafted Pocket T-Shirts
Honolulu, HI - June 22, 2025 - Pockefy Registered is redefining surf-inspired apparel through exceptional product quality, conscious design, and its commitment to social impact. It brings a fresh take to surf lifestyle staples by combining visual simplicity with ethical production for those who value sustainability, durability, and standout style.
Image: https://www.globalnewslines.com/uploads/2025/06/cce40bc1554985e17a9076f02e181883.jpg
The brand's defining design element is its signature pocket detailing, featuring minimalist patterns or surf-inspired motifs that add a unique…
Critically Acclaimed Legal Thrillers Bring Gripping Realism to the Courtroom: Mo …
Image: https://www.globalnewslines.com/uploads/2025/06/4959073d2b980b297f538b31033e3f13.jpg
Three riveting legal thrillers from seasoned prosecutor-turned-author Morley Swingle are set to launch simultaneously on June 21, 2025, introducing readers to Wyatt Blake - a complex, sharp-witted defense attorney navigating the moral gray zones of justice in the high-stakes courtrooms of fictional Panorama Springs, a ski resort town nestled in the Colorado Rockies.
In the tradition of legendary legal minds like Perry Mason and Jack Brigance, Wyatt Blake headlines Choice…
Narrow Path Roofing & Construction Sets the Standard for Excellence in Cartersvi …
Image: https://www.globalnewslines.com/uploads/2025/06/1750445438.jpg
Narrow Path Roofing & Construction continues to deliver exceptional craftsmanship and customer satisfaction throughout Bartow County, earning a trusted reputation among homeowners and businesses alike. Specializing in comprehensive roofing solutions, the company has become a go-to name for those searching for a reputable Roofer Cartersville.
Known for its prompt response times, high-quality materials, and experienced crews, Narrow Path Roofing & Construction addresses everything from storm damage restoration to full…
James H. Cole Home For Funerals, Inc. Continues to Provide Compassionate End-of- …
Image: https://www.globalnewslines.com/uploads/2025/06/1750446893.jpg
James H. Cole Home For Funerals, Inc. has long been a trusted name in the Detroit community, offering compassionate and professional funeral care. Through decades of dedicated service, the mortuary has established a reputation for respectfully handling delicate moments and attending to the unique needs of families during difficult times. The company continues to evolve its offerings to meet the changing expectations of the community it serves.
Honoring Traditions…
More Releases for ProteLight
Breath Freshener Spray Market Strategic Insights Of Developing Industry Growing …
The latest research on Breath Freshener Spray Market provides a thorough examination of the most current developments in the Breath Freshener Spray and the key dynamics that are driving growth. It is a research report that examines market drivers, restraints, challenges, risks, and development prospects in the global market for Breath Freshener Spray. The global Breath Freshener Spray market report is a systematic study of the Breath Freshener Spray industry,…
Antimicrobial Peptides Market 2022 : Size, Growth Opportunities, Current Trends, …
"Infinity Business Insights publishes a report which aims to assess the Global Antimicrobial Peptides Market Research Report 2022 which includes Future Trends, Size, Share, Past, Current Data and In-depth Analysis and Forecasts, Current and Future Growth Prospects from 2022 to 2028 with Market Deciding Factors Analysis untapped potential, revenue potential, regional analysis, trends stimulating the segment's growth, product demand and consumption patterns in global markets. The impact of the COVID-19…
Antimicrobial Peptides Market Growth, Competitive Analysis and Forecast 2027| An …
The global Antimicrobial Peptides market size is expected to reach US$ 6 million by the end of 2027, with a CAGR of 5.4% during 2021-2027. Antimicrobial peptides (AMPs), also called host defence peptides (HDPs) are part of the innate immune response found among all classes of life. Fundamental differences exist between prokaryotic and eukaryotic cells that may represent targets for antimicrobial peptides. These peptides are potent, broad spectrum antibiotics which…
Animal Antimicrobial Peptides Market global outlook and forecast 2021 -2027
The Global Animal Antimicrobial Peptides Market research report is a careful examination of the worldwide industry which has been a region of enthusiasm for a Animal Antimicrobial Peptides makers, organizations, authorities, chiefs, and likely speculators, and analysts. The report profoundly lights up noteworthy features in the business, including a contention situation, condition, portions, showcase size, share, gainfulness, development potential, and advancements.
The report likewise spins around the…
Plant Antimicrobial Peptides Market global outlook and forecast 2021 -2027| Prot …
The Global Plant Antimicrobial Peptides Market research report is a careful examination of the worldwide industry which has been a region of enthusiasm for a Plant Antimicrobial Peptides makers, organizations, authorities, chiefs, and likely speculators, and analysts. The report profoundly lights up noteworthy features in the business, including a contention situation, condition, portions, showcase size, share, gainfulness, development potential, and advancements.
The report likewise spins around the…
Antimicrobial Peptides Market Regional Outlook by 2027| AnaSpec, AMP Biotech, Ph …
QY Research has Published Latest Trending Report on Global Antimicrobial Peptides Market
Los Angeles, United State, – The report titled Antimicrobial Peptides Market is one of the most comprehensive and important additions to QY Research’s archive of market research studies. It offers detailed research and analysis of key aspects of the global Antimicrobial Peptides market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities…
